Sarepta Therapeutics has appointed Shamim Ruff to serve as Vice President, Regulatory Affairs and Quality. Prior to joining, Ruff served as Vice President and Head of Global Regulatory Affairs for the Oncology unit at sanofi-aventis. From 2007-2011, Ruff was Executive Director of Global Regulatory Affairs at Amgen, Inc. Prior to that, she worked at Abbott Laboratories as Senior Director of Global Regulatory Affairs. Ruff’s earlier roles include serving as Director of Global Regulatory Affairs and Quality Assurance at AstraZeneca as well as serving as a Regulatory Compliance Executive at Janssen Pharmaceuticals Limited.
Ruff received her M.Sc. in Analytical Chemistry and Instrumentation at the University of Loughborough and her B.Sc. in Combined Sciences (Chemistry and Biology) at the University of Leicester.
About Sarepta Therapeutics
Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs.